Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Linolenic acid + polaprezinc is a combination of two active ingredients: linolenic acid, an essential omega-3 polyunsaturated fatty acid, and polaprezinc, a chelated complex of zinc and L-carnosine. Linolenic acid is primarily used for nutritional supplementation to address dietary deficiencies or imbalances in omega-3 fatty acids. It has demonstrated cardiovascular benefits by reducing inflammation, lowering blood pressure, improving endothelial function, and decreasing the risk of arrhythmias and thrombosis[10][8]. Polaprezinc is approved in Japan for the treatment of peptic ulcer disease and dyspepsia; it acts as a mucosal protective agent with antioxidant, anti-inflammatory, and tissue-healing properties[1][6]. The combination may be intended to provide both gastrointestinal protection (from polaprezinc) and systemic anti-inflammatory or nutritional support (from linolenic acid), though no specific branded pharmaceutical product containing both agents was identified in major regulatory databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on linolenic acid + polaprezinc.